Patrick Vollmar

Dr. Patrick Vollmar is a global strategic leader in the pharmaceutical industry with over 12 years of experience.2 He previously held the position of Brand Director - Customer Experience Lead Ligelizumab Launch in Chronic Spontaneous Urticaria at Novartis.1 However, in March 2022, he announced his departure from Novartis after 12 years with the company, during which he held six different roles across three countries and was involved in three product launches.3

Currently, Dr. Vollmar is working as an Executive Director for zeposia commercial MS at Bristol Myers Squibb, a position he has held since April 2022.12 His career at Novartis included various roles such as Brand Director US Aimovig (Migraine), Area Business Leader Neuroscience, Account Manager Gilenya, and Global Brand Manager Gilenya.1

Dr. Vollmar's educational background includes a PhD in Neuroscience, which he completed at Technische Universität München, focusing on Multiple Sclerosis and Alzheimer's disease.1 He also conducted research at the Università degli Studi di Padova and studied Biopsychology at Ruhr-Universität Bochum.1

Throughout his career, Dr. Vollmar has demonstrated expertise in multiple sclerosis, neuroscience, and pharmaceutical marketing.14 He is known for his people-first approach in his leadership roles within the pharmaceutical industry.2